ALISHA MASON: Open Payments
NPI 1023529443 · RIPLEY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$774 in 43 payments from 13 companies in 2025. Trend: 2023 $500 · 2024 $444 · 2025 $774
Food & beverage: $774
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $82 |
| Novo Nordisk Inc | 5 | $79 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Amgen Inc. | 4 | $65 |
| Lilly USA, LLC | 4 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
Products named: JARDIANCE, FARXIGA, Kerendia, NEXLETOL, CAPLYTA, GEMTESA, Wegovy, TRELEGY ELLIPTA.
Industry payments across MS — which companies pay providers there.
